medRxiv Preprint Server
April 23, 2026
Willys Cantenys, Zeynep Yoldas, Luc Masset et al.
preprint
Background Ketamine is a rapid-acting antidepressant that produces acute dissociative symptoms. In routine care, the respective contributions of therapeutic expectations and dissociative symptoms to antidepressant response, and the directionality of their associations with depressive symptom change, remain poorly characterized.
Biologie aujourd'hui
2023
Philippe Fossati
Thirty percent of depressed patients are treatment resistant (TRD) suggesting the need of new therapeutic strategy. Recently, it has been shown that ketamine, an anesthetic agent with dissociative effects, has potent and rapid antidepressant properties. Ketamine is a ionotropic glutamatergic NMDA antagonist that inhibits gabaergic neurons. Its antidepressant effect peaks at 24 h post-treatment....
Sleep
November 29, 2022
Luc Masset, Milan Nigam, Anne Ladarre et al.
9 citations
Dream's emotions could exert a major role in desensitizing negative emotions. Studying emotional dynamics (how emotions fluctuate across time) during rapid eye movement (REM) sleep could provide some insight into this function. However, studies so far have been limited to dream reports. To bypass this limit, REM sleep behavior disorder (RBD), in which participants enact their dreams, enables...
JAMA Psychiatry
September 28, 2022
Hugo Bottemanne, Orphée Morlaàs, Anne Claret et al.
59 citations
Key Points Question What are the effects of ketamine on belief updating in patients with treatment-resistant depression (TRD)? Findings This case-control study in patients with TRD showed that belief updating became more optimistically biased as soon as 4 hours after a first ketamine infusion. This early cognitive effect of ketamine was formalized by stronger asymmetrical reinforcement learning...
Journal of Clinical Sleep Medicine
April 12, 2022
C. Mallet, Christina F. Chick, R. Maatoug et al.
Posttraumatic nightmares may exacerbate and perpetuate the daytime symptoms of posttraumatic stress disorder and might represent a therapeutic target. The therapeutic strategy of memory reconsolidation using the β-adrenergic receptor blocker propranolol associated with re-exposure psychotherapy is a promising treatment in patients with posttraumatic stress disorder. Previous studies have...
L'Encephale
November 12, 2020
Hugo Bottemanne, Anne Claret, Philippe Fossati
10 citations
The hypothesis of monoaminergic deficiency has long dominated the conceptual framework for the development of new antidepressant strategies, but the limits of conventional antidepressant treatments targeting monoaminergic signaling have motivated the search for new antidepressant pathways. The success of ketamine in the management of depressive disorders has provoked a renewed interest in...
Hugo Bottemanne, Orphée Morlaàs, Anne Claret et al.
4 citations
preprint
Treatment resistant depression (TRD) is a tremendous health problem that has encouraged novel treatment strategies involving sub-anesthetic ketamine infusions. While ketamine induces rapid and sustained clinical improvement, its cognitive effects are less well known. Here we tested if ketamine alters the negative expectancies about the future that are insensitive to disconfirming information,...
Zeynep Yoldas, Willys Cantenys, Morgane Tronche et al.
preprint
Background: Facial emotion recognition deficits are well defined in depression but understudied in treatment-resistant depression (TRD). Over the past decades, subanesthetic doses of ketamine have emerged as an effective treatment for TRD, but its effect on affective processing is still little known. Approaches from computational psychiatry, such as sequential evidence sampling models of...